LCC-21, a novel multitarget small molecule, successfully suppressed VEGFA, CTNNB1, MMP7, and CD44 signatures in CRC cell lines, thus suggesting that LCC-21 might be a potential novel candidate compound for inhibiting the VEGFA/CTNNB1/MMP7/CD44 signaling pathway in CRC. The gene discussed is CD44; the disease is colorectal carcinoma.